Vanda Pinto, PhD, science writer —

​​Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.

Articles by Vanda Pinto

Valted Seq Acquires Rights to Develop Biomarker Assays

D&D Pharmatech’s new subsidiary, Valted Seq, announced it has acquired exclusive rights from Johns Hopkins University to develop multiple biomarker assays for the evaluation and management of neurodegenerative diseases, including Parkinson’s. “There are currently no clinically accepted biomarker assays available for Parkinson’s disease. An assay capable of…